截至2025年12月8日收盘，华东医药（000963）报收于42.52元，较前一交易日上涨0.93%，最新总市值 为745.81亿元。该股当日开盘42.58元，最高43.07元，最低42.09元，成交额达2.94亿元，换手率为 0.39%。 《关于全资子公司产品及合作产品纳入国家医保及商保创新药目录的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 公司近日发布公告称，2025年12月7日，国家医保局等部门发布新版药品目录及商业健康保险创新药品 目录。华东医药全资子公司中美华东的乌司奴单抗注射液调整至常规目录管理，支付范围保持不变。公 司合作产品塞纳帕利胶囊、戊二酸利那拉生酯胶囊纳入协议期内谈判药品目录，泽沃基奥仑赛注射液纳 入商保创新药目录。新版目录自2026年1月1日起执行，相关产品的纳入预计有利于未来市场推广，但对 公司近期业绩无重大影响。 ...

中证报中证网讯(记者傅苏颖)12月7日，华东医药（000963）全资子公司华东医药(杭州)有限公司宣布与 贵州生诺生物科技有限公司及其全资子公司上海生诺医药科技有限公司、江苏太瑞生诺生物医药科技有 限公司(三家合作公司合称为"生诺医药")，就生诺医药产品戊二酸利那拉生酯胶囊及其他剂型达成中国 大陆地区的独家商业化合作。 国家医保局12月7日披露，利那拉生酯针对反流性食管炎适应症和PARP抑制剂塞纳帕利(派舒宁)被纳入 2025年版国家医保目录。同时，泽沃基奥仑赛注射液(商品名：赛恺泽)被纳入2025年版商保创新药目 录，华东医药组建了独立专业、全方位的商业化团队全面推广赛恺泽，利用中国多层次保险体系，提高 患者可及性。目前，赛恺泽完成认证及备案的医疗机构已覆盖全国20多个省市。 近年来，华东医药创新研发聚焦肿瘤、内分泌及自身免疫三大核心治疗领域，通过自主研发、外部合作 和产品授权引进等方式，持续丰富覆盖研发全周期的差异化创新产品管线，为中长期发展提供新动能。 公司的自主研发创新能力持续提升，创新药研发中心正在推进90余项管线项目。 利那拉生酯是生诺医药与Cinclus Pharma合作开发的新一代钾离子竞争性 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 2025年12月07日，国家医保局、人力资源社会保障部发布【关于印发《国家基本医疗保险、生育保险和 工伤保险药品目录》以及《商业健康保险创新药品目录》（2025年）的通知（医保发〔2025〕33号）】 （以下简称新版药品目录、商保创新药目录），华东医药股份有限公司（以下简称"公司"）部分产品及 合作产品被纳入新版药品目录及商保创新药目录。 公司全资子公司杭州中美华东制药有限公司（以下简称"中美华东"）乌司奴单抗注射液调整至常规目录 管理，支付范围较前一版药品目录有所变动。公司合作产品塞纳帕利胶囊、戊二酸利那拉生酯胶囊被纳 入协议期内谈判药品部分，泽沃基奥仑赛注射液被纳入商保创新药目录。 详细情况如下： 注：企业申请价格保密的，医保支付标准一栏标识为*。 二、纳入商保创新药目录情况 四、对公司的影响 公司上述子公司的其他已纳入国家医保目录的产品本次未发生目录调出变动。新版药品目录自2026年1 月1日起正式执行，医保支付标准、医保报销细则等相关信息，需以国家医疗保障 ...

Core Points - The announcement details that certain products from East China Pharmaceutical Co., Ltd. and its wholly-owned subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd., have been included in the new National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs [1][4] - The inclusion of the products is expected to aid in market promotion, although it will not have a significant impact on the company's recent performance [4] Group 1: New Inclusion in Drug Catalogs - The company's product, Ustinumab injection, has been adjusted to regular catalog management, with changes in payment scope compared to the previous version [1][2] - Collaborative products, Senapali capsules and Butanedioic acid linaclotide capsules, have been included in the negotiated drug section, while Zewokiorunsai injection is part of the commercial health insurance innovation drug catalog [1][3] Group 2: Impact on the Company - Other products already included in the National Medical Insurance catalog have not been removed in this update [4] - The new drug catalog will take effect from January 1, 2026, and the specific reimbursement standards and details will be based on announcements from relevant government departments [4]

（编辑 王江浩） 证券日报网讯 12月7日晚间，华东医药发布公告称，公司全资子公司杭州中美华东制药有限公司乌司奴 单抗注射液调整至常规目录管理，支付范围较前一版药品目录有所变动；公司合作产品塞纳帕利胶囊、 戊二酸利那拉生酯胶囊被纳入协议期内谈判药品部分，泽沃基奥仑赛注射液被纳入商保创新药目录。 ...

来源：环球网 新版目录将于2026年1月1日起全面实施，将让更多中国卵巢癌患者以可负担的成本，获得长期生存的希 望。 12月7日，《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（以下简称新版药品目 录）以及《商业健康保险创新药品目录（2025年）》（以下简称商保创新药目录）正式发布，戊二酸利 那拉生酯胶囊成功入选新版药品目录。 此外，华东医药独家商业化的塞纳帕利胶囊与泽沃基奥仑赛注射液赛恺泽®也分别进入新版药品目录、 首个商保创新药目录。至此，华东医药共有三款创新药产品被纳入新版药品目录或首版商保创新药目 录。 ...

利那拉生酯是生诺医药与Cinclus Pharma合作开发的新一代钾离子竞争性酸阻滞剂类药物(P-CAB)，用于 治疗消化系统疾病。目前，该药物针对反流性食管炎适应症已在国内获批并成功进入2025年国家医保目 录，同时十二指肠溃疡及幽门螺杆菌感染根除适应症正在开展临床三期。在反流性食管炎适应症成功商 业化的基础上，随着其临床研究的持续推进，未来该药物有望实现适应症的进一步扩增，市场潜力与临 床价值将进一步凸显。 临床研究表明，利那拉生酯在口服后不仅能迅速起效，实现长时间、高强度的胃酸抑制，更展现出良好 的整体安全性，为其临床应用提供了重要保障。目前，P-CAB已被《中国胃食管反流病专家共识(2020 年版)》和《2023年中国胃食管反流病诊疗规范》等临床指南列为治疗胃食管反流病(GERD)的首选药 物，显示出该类药物的治疗价值正获得广泛认可。 12月7日，证券时报记者获悉，华东医药（000963）全资子公司华东医药(杭州)有限公司宣布与贵州生 诺生物科技有限公司及其全资子公司上海生诺医药科技有限公司，江苏太瑞生诺生物医药科技有限公司 (下称"生诺医药")，就生诺医药产品戊二酸利那拉生酯胶囊及其他剂型达成中国大 ...

Corporate Announcements - China Pacific Insurance announced that Vice President Yu Ze is under investigation for serious violations of discipline and law, but this will not affect the company's management [2] - Guanglian Aviation reported that its controlling shareholder and chairman Wang Zengduo has had his detention lifted, allowing him to resume his duties, with normal operations continuing [3] - China Communications Construction Company clarified that it bears no repayment or guarantee obligations related to overdue financial products linked to its controlling shareholder, and its operations remain normal [4] - Annie Co. is planning a change in control, with stock trading resuming on December 8, 2025, after a share transfer agreement is signed [5] - Guoao Technology announced that its actual controller is planning a change in control, leading to a temporary suspension of its stock [6] - ST Tianrui terminated its planned change in control due to a lack of consensus, with stock resuming trading on December 8, 2025 [7] Industry Developments - Double Star New Materials noted that leading companies in the BOPET industry have reached a consensus on production cuts to balance supply and demand, although the sustainability of long-term price increases remains uncertain [8] - First Venture received a notice of administrative penalty for failing to diligently supervise a bond project, resulting in fines and warnings, but this will not significantly impact its operations [12] - China Chemical announced that its nylon new materials project has reached full production capacity, enhancing efficiency and market competitiveness [14] Pharmaceutical Sector Updates - Hengrui Medicine reported that nine of its drugs have been included in the national medical insurance directory, with a total expected sales of approximately 8.66 billion yuan for 2024 [15] - Junshi Biosciences announced that its products have received new indications and have been included in the national medical insurance directory, enhancing market accessibility [16] - Huadong Medicine's subsidiary has had its products included in the national medical insurance and commercial insurance innovation drug directories, aiding market promotion [17] - Aidi Pharmaceutical's two innovative HIV drugs have been renewed for inclusion in the national medical insurance directory, with specific pricing established [18] - ZhiXiang JinTai's monoclonal antibody has been included in the national medical insurance directory, which is expected to positively impact future sales [19] - Fosun Pharma announced multiple products have been newly included in the national medical insurance directory, which is anticipated to positively influence future performance [20] - Zejing Pharmaceutical's drug has been included in the national medical insurance directory, which will enhance affordability and market promotion [21] - Micron Biologics' product has been included in the national medical insurance directory, with no significant impact on current performance expected [22] Shareholder Commitments - Tianci Materials' controlling shareholder has committed not to reduce his shareholding in the company for six months, reflecting confidence in the company's future [23] Major Contracts - Guangqi Technology's subsidiary signed contracts worth 696 million yuan for the mass production of metamaterials, expected to impact the company's performance in 2026 [24]

12月7日，华东医药（000963）股份有限公司(以下简称"华东医药"或公司)全资子公司华东医药(杭州)有 限公司宣布与贵州生诺生物科技有限公司及其全资子公司上海生诺医药科技有限公司，江苏太瑞生诺生 物医药科技有限公司(以下简称"生诺医药")，就生诺医药产品戊二酸利那拉生酯胶囊及其他剂型达成中 国大陆地区的独家商业化合作。 利那拉生酯商业化前景值得期待。据国元证券研报，伏诺拉生作为全球首款P-CAB药物，2024年销售额 已突破50亿元，验证了该靶点的临床价值与市场潜力。利那拉生酯可依托华东医药在国内成熟的销售网 络与渠道资源，快速推进终端覆盖。叠加其反流性食管炎适应症已被纳入2025年国家医保目录，药物可 及性将大幅提升。 华东医药此次战略性引进利那拉生酯，彰显了其瞄准前沿疗法、持续加码消化赛道的决心。作为国内深 耕消化领域的药企，华东医药深谙临床未满足的需求，其选择利那拉生酯正体现了对该产品市场潜力的 高度认可。依托华东医药强大的商业化平台，利那拉生酯不仅有望快速放量，更将进一步完善华东医药 在消化疾病领域的产品矩阵，巩固其行业领先地位。 双目录纳入三款创新产品 值得一提的是，同日，《国家基本医疗保险、生 ...

华东医药公告称，国家医保局、人社部发布新版药品目录及商保创新药目录，公司部分产品及合作产品 被纳入。全资子公司中美华东乌司奴单抗注射液调整至常规目录管理，支付范围有变动；合作产品塞纳 帕利胶囊、戊二酸利那拉生酯胶囊被纳入协议期内谈判药品部分，泽沃基奥仑赛注射液被纳入商保创新 药目录。新版药品目录2026年起执行，上述产品纳入对近期业绩无重大影响，预计助于未来市场推广。 ...